IMMUTEP LIMITED — Board/Management Information 2011

Jun 30, 2011

ASX/Media Release (Code: PRR) 1 July 2011

==> picture [202 x 37] intentionally omitted <==

Prima BioMed Changes Location of Registered Office & Resignation of Joint Company Secretary

Please note that effective immediately, Prima BioMed Limited has today changed the location of its registered office and principle place of business to:

Level 7, 151 Macquarie Street Sydney, New South Wales 2000

Telephone: +61 (0)2 9276 1224

Facsimile: +61 (0)2 9276 1284

Further to the change of addresses, the Company wishes to advise that Mr. Phillip Hains is resigning today as Joint Company Secretary of Prima BioMed Limited and its subsidiaries. Mr Hains has served as Company Secretary Prima since March 2002.

The Company and Board of Directors wishes to extend their appreciation to Mr. Hains and acknowledge his extensive service to the Company, and wishes him will in his future endeavors.

Mr Ian Bangs, currently Joint Company Secretary and Chief Financial Officer, will continue in the role as Company Secretary.

END

For further information please contact:

Martin Rogers Chief Executive Officer Prima BioMed Ph: +61 (0)2 9276 1242 E: martin.rogers@primabiomed.com.au

Mr James Moses Investor and Media Relations Mandate Corporate Ph: +61 (0)420 991 574 E: james@mandatecorporate.com.au

Website: www.primabiomed.com.au

Prima BioMed Limited , Level 7, 151 Macquarie Street, Sydney, NSW 2000 Ph: +61 (0)2 9276 1224 Fax: +61 (0)2 9276 1284 www.primabiomed.com.au ABN: 90 009 237 889

About CVac[TM] Ovarian Cancer Treatment

CVac™ is Prima BioMed’s core product. It is a vaccine therapy treatment for ovarian cancer sufferers that is administered post-surgery and post-chemotherapy to delay the relapse and control the metastases of the cancer. There is a large un-met medical need for new treatments for ovarian cancer which has a very high morbidity rate, and there are currently no maintenance-based therapy products commercially available.

The Company has commenced its Phase IIb Trial for CVac™ with the US FDA and plans to commence a Phase III Clinical Trial for CVac™ in Europe and the US this year. The Phase IIb and Phase III Trials aim to further confirm the ability of CVac™ to reduce the instance of relapse in ovarian cancer patients, control the metastases of the cancer and increase the life expectancy of patients.

Prima’s ultimate goal is to commercialise CVac™ into the multi-billion dollar global pharmacy oncology market. The global market for ovarian cancer therapeutics was valued at US$2.1b in 2007 and was estimated to have grown to US$3.6b by 2010.

Regulatory approval and commercialization of CVac[TM ] is the core focus for Prima.

About Prima BioMed

Prima BioMed is an ASX listed Australian health care company. The Company is focused on technologies in the fields of cancer immunotherapy and immunology.

Prima’s lead product is CVac[TM ] ovarian cancer therapy treatment. It has completed two successful clinical trials and is progressing toward eventual commercialization in the United States, Australia, Europe, and globally.

The Company’s broader, long term goal is to develop commercial cancer treatment technologies and programs for global markets.

Prima BioMed Limited , Level 7, 151 Macquarie Street, Sydney, NSW 2000 Ph: +61 (0)2 9276 1224 Fax: +61 (0)2 9276 1284 www.primabiomed.com.au ABN: 90 009 237 889